• Elena Daniela SEMEN “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • I. PRUTIANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • G. LUTA Regional Institute of Oncology, Iasi
  • Manuela CIOCOIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi


The overexpression of vimentin is linked to tumors with low differentiation, metastatic diseases, and reduced overall survival. The precise function of transgelin, an actin-binding protein, in the development of cancer is still debatable. Nevertheless, its participation in the mobility, differentiation and programmed cell death of malignant cells has been well-established. Material and methods: To investigate transgelin and transgelin expression, we used glioblastoma U87 cell line 2D culture. We conducted immunofluorescence staining to examine cultured cells. Results: the studied proteins were co-expressed in the studied cell line. Conclusions: How transgelin is expressed in cancerous cells is similar to the expression of vimentin. This similarity could suggest that transgelin may serve as an indicator of the level of aggression in cancer.

Author Biographies

Elena Daniela SEMEN, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

I. PRUTIANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (I)

G. LUTA, Regional Institute of Oncology, Iasi


Manuela CIOCOIU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)


1. Zong H, Verhaak RG, Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn 2012; 12(4): 383-394 / doi:10.1586/erm.12.30.
2. Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. Eur J Cancer 2014; 50(13): 2309-2318 / doi:10.1016/j.ejca.2014.05.019.
3. Aum DJ, Kim DH, Beaumont TL, et al. Molecular and cellular heterogeneity: The hallmark of glio-blastoma. Neurosurg Focus 2014; 37(6): E11 / doi:10.3171/ 2014. 9.FOCUS14521.
4. Phua DCY, Humbert PO, Hunziker W. Vimentin regulates scribble activity by protecting it from proteasomal degradation. Mol Biol Cell 2009; 20: 2841-2855 / doi:10.1091/mbc.e08-02-0199.
5. Battaglia RA, Delic S, Herrmann H, Snider NT. Vimentin on the move: new developments in cell migration. F1000Research 2018; 7 F1000 Faculty Rev-1796 / doi:10.12688/f1000research.15967.1
6. Esue O, Carson AA, Tseng Y, et al. A direct interaction between actin and vimentin filaments mediated by the tail domain of vimentin. J Biol Chem 2006; 281(41): 30393-30399 / doi:10.1074/ jbc.M605452200.
7. Strouhalova K, Přechová M, Gandalovičová A, et al. Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. Cancers (Basel) 2020; 12(1): 184 / doi:10.3390/cancers12010184.
8. Cheng F, Shen Y, Mohanasundaram P, et al. Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-β-Slug signaling. Proc Natl Acad Sci USA 2019; 113(30): E4320-4327 / doi:10.1073/pnas.1519 197113.
9. Zhao Y, Yan Q, Long X, et al. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008; 26: 571-577 / doi:10.1002/cbf.1478.
10. Hemalatha A, Suresh TN, Harendra Kumar ML. Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters. Indian J. Cancer 2013; 50(3): 189-194/ doi: 10.4103/0019-509X.118724.
11. Niknami Z, Muhammadnejad A, Ebrahimi A, et al. Significance of E-cadherin and Vimentin as epi-thelial-mesenchymal transition markers in colorectal carcinoma prognosis. EXCLI Journal 2020; 19: 917-926 / doi:10.17179/ excli 2020-1946.
12. Ngan C, Yamamoto H, Seshimo I, et al. Quantitative evaluation of vimentin expression in tumor stroma of colorectal cancer. Br J Cancer 2007; 96: 986-992 / doi:10.1038/sj.bjc.6603651.
13. Rao D, Kimler BF, Nothnick WB, Davis MK, Fan F, Tawfik O. Transgelin: a potentially useful diag-nostic marker differentially expressed in triple-negative and non-triple-negative breast cancers. Hum Pathol 2015; 46(6): 876-883 / doi:10.1016/j.humpath.2015.02.015
14. Zhang Y, Ye Y, Shen D et al. Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. Cancer Sci 2010; 101(2): 523-529 / doi: 10.1111/j.1349 -7006. 2009. 01424.x.
15. Dvorakova M, Nenutil R, Bouchard P. Transgelins, cytoskeletal proteins implicated in different aspects of cancer development. Expert Rev Proteomics. 2014; 11(2): 149-165 / doi: 10.1586/ 14789450.2014.860358.
16. Fleming M, Ravula S, Tatishchev S, Wang H. Colorectal carcinoma: Pathological aspects. J Gastro-intest Oncol 2012; 3(3): 153-173 / doi: 10.3978/j.issn. 2078 6891. 2012.030.
17. Sun C, Zhang K, Ni C et al. Transgelin promotes lung cancer progression via activation of cancer-associated fibroblasts with enhanced IL-6 release. Oncogenesis 2023; 12: 18 / doi:10.1038/s41389-023-00463-5
18. Shi J, Ren M, She X, et al. Transgelin-2 contributes to proliferation and progression of hepatocellular carcinoma via regulating Annexin A2. Biochem Biophys Res Commun. 2020; 523(3): 632 638. / doi:10.1016/j.bbrc.2020.01.028
19. Samalia PD. Transgelin: Discovering its Role in Prostate Cancer Progression (Thesis, Doctor of Philosophy, 2013). University of Otago. Retrieved from
20. Yang B, Chen Q, Wan C, et al. Transgelin Inhibits the Malignant Progression of Esophageal Squamous Cell Carcinomas by Regulating Epithelial-Mesenchymal Transition. Front Oncol 2011; 11: 709486 / doi:10.3389/fonc.2021.709486.
21. Zhou Q, Jiang X, Yan W, Dou X. Transgelin 2 overexpression inhibits cervical cancer cell invasion and migration. Mol Med Rep 2019; 19(6): 4919-4926 / doi:10.3892/mmr.2019.10116.
22. Lin Y, Phillip J, Buckhaults I. et al. Association of the Actin-Binding Protein Transgelin with Lymph Node Metastasis in Human Colorectal Cancer. Neoplasia 2009; 11; 864-873 / doi: 10.1593 /neo.095 42.
23. Tang DD, Gerlach BD. The roles and regulation of the actin cytoskeleton, intermediate filaments and microtubules in smooth muscle cell migration. Res. 2017; 18: Article 54 / doi:10.1186/s12931-017-0544-7.
24. Winter M, Meignan S, Völkel P, et al. Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment. Cells 2021; 10(6): 1504 / doi:10.3390/ cells10061504.
25. Becker AP, Sells BE, Haque SJ, Chakravarti A. Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. Cancers 2021; 13(4): 761 / doi:10.3390/cancers13040761.
26. Lepekhin EA, Eliasson C, Berthold CH, Berezin V, Bock E, Pekny M. Intermediate Filaments Regulate Astrocyte Motility. J. Neurochem 2001; 79: 617-625 / doi:10.1046/j.1471-4159.2001.00595.x.
27. Dvořáková M, Jeřábková J, Procházková I, Lenčo J, Nenutil R, Bouchal P. Transgelin is upregulated in stromal cells of lymph node positive breast cancer. J Proteomics 2016; 132: 103-111 / doi: 10.1016/j.jprot.2015.11.025.